Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplem… Read more
Daewoong Pharma (069620) - Net Assets
Latest net assets as of September 2025: ₩1.00 Trillion KRW
Based on the latest financial reports, Daewoong Pharma (069620) has net assets worth ₩1.00 Trillion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩2.26 Trillion) and total liabilities (₩1.26 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩1.00 Trillion |
| % of Total Assets | 44.42% |
| Annual Growth Rate | 7.53% |
| 5-Year Change | 33.33% |
| 10-Year Change | 59.76% |
| Growth Volatility | 8.95 |
Daewoong Pharma - Net Assets Trend (2007–2024)
This chart illustrates how Daewoong Pharma's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Daewoong Pharma (2007–2024)
The table below shows the annual net assets of Daewoong Pharma from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩926.98 Billion | +15.44% |
| 2023-12-31 | ₩802.97 Billion | +8.33% |
| 2022-12-31 | ₩741.22 Billion | +5.53% |
| 2021-12-31 | ₩702.41 Billion | +1.03% |
| 2020-12-31 | ₩695.25 Billion | +9.33% |
| 2019-12-31 | ₩635.92 Billion | +4.62% |
| 2018-12-31 | ₩607.81 Billion | -3.76% |
| 2017-12-31 | ₩631.54 Billion | +4.46% |
| 2016-12-31 | ₩604.55 Billion | +4.19% |
| 2015-12-31 | ₩580.24 Billion | +27.38% |
| 2014-12-31 | ₩455.51 Billion | +4.01% |
| 2013-12-31 | ₩437.96 Billion | +13.29% |
| 2012-12-31 | ₩386.59 Billion | +6.67% |
| 2011-12-31 | ₩362.42 Billion | +29.97% |
| 2008-12-31 | ₩278.85 Billion | +3.44% |
| 2007-12-31 | ₩269.57 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Daewoong Pharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 63567448694000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩635.67 Billion | 80.00% |
| Other Components | ₩158.97 Billion | 20.00% |
| Total Equity | ₩794.64 Billion | 100.00% |
Daewoong Pharma Competitors by Market Cap
The table below lists competitors of Daewoong Pharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ye Chiu Metal Recycling China Ltd
SHG:601388
|
$589.47 Million |
|
Shenzhen JingQuanHua Electronics Co Ltd
SHE:002885
|
$589.54 Million |
|
Rumble Inc.
NASDAQ:RUM
|
$589.56 Million |
|
Bilia AB (publ)
ST:BILI-A
|
$589.68 Million |
|
Devyani International Limited
NSE:DEVYANI
|
$589.45 Million |
|
Viohalco S.A
BR:VIO
|
$589.42 Million |
|
Smarter Microelectronics (Guangzhou) Co. Ltd. A
SHG:688512
|
$589.31 Million |
|
Insteel Industries Inc
NYSE:IIIN
|
$589.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Daewoong Pharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 802,974,720,740 to 794,639,762,000, a change of -8,334,958,740 (-1.0%).
- Net income of 24,734,510,690 contributed positively to equity growth.
- Dividend payments of 7,740,654,000 reduced retained earnings.
- Other factors decreased equity by 25,328,815,430.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩24.73 Billion | +3.11% |
| Dividends Paid | ₩7.74 Billion | -0.97% |
| Other Changes | ₩-25.33 Billion | -3.19% |
| Total Change | ₩- | -1.04% |
Book Value vs Market Value Analysis
This analysis compares Daewoong Pharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.33x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.19x to 2.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩50328.95 | ₩160600.00 | x |
| 2018-12-31 | ₩47877.03 | ₩160600.00 | x |
| 2019-12-31 | ₩50316.93 | ₩160600.00 | x |
| 2020-12-31 | ₩51194.76 | ₩160600.00 | x |
| 2021-12-31 | ₩51816.40 | ₩160600.00 | x |
| 2022-12-31 | ₩54928.72 | ₩160600.00 | x |
| 2023-12-31 | ₩69785.84 | ₩160600.00 | x |
| 2024-12-31 | ₩69061.46 | ₩160600.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Daewoong Pharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.74%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 2.49x
- Recent ROE (3.11%) is below the historical average (8.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 22.35% | 12.17% | 1.23x | 1.49x | ₩32.57 Billion |
| 2008 | 12.05% | 6.01% | 1.13x | 1.78x | ₩5.61 Billion |
| 2011 | 14.00% | 7.06% | 1.43x | 1.39x | ₩14.34 Billion |
| 2012 | 8.89% | 5.09% | 1.39x | 1.26x | ₩-4.24 Billion |
| 2013 | 13.47% | 8.56% | 1.18x | 1.34x | ₩15.03 Billion |
| 2014 | 7.12% | 4.29% | 1.06x | 1.57x | ₩-12.76 Billion |
| 2015 | 8.94% | 5.11% | 0.89x | 1.97x | ₩-5.08 Billion |
| 2016 | 5.40% | 3.05% | 0.77x | 2.29x | ₩-22.98 Billion |
| 2017 | 6.08% | 3.29% | 0.79x | 2.34x | ₩-20.36 Billion |
| 2018 | -3.07% | -1.47% | 0.85x | 2.44x | ₩-64.57 Billion |
| 2019 | 4.24% | 1.98% | 0.89x | 2.40x | ₩-29.93 Billion |
| 2020 | 2.31% | 1.21% | 0.77x | 2.48x | ₩-42.35 Billion |
| 2021 | 4.30% | 2.14% | 0.81x | 2.47x | ₩-32.70 Billion |
| 2022 | 6.95% | 3.30% | 0.82x | 2.57x | ₩-18.56 Billion |
| 2023 | 15.16% | 8.85% | 0.88x | 1.95x | ₩41.44 Billion |
| 2024 | 3.11% | 1.74% | 0.72x | 2.49x | ₩-54.73 Billion |
Industry Comparison
This section compares Daewoong Pharma's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $472,965,132,317
- Average return on equity (ROE) among peers: 3.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Daewoong Pharma (069620) | ₩1.00 Trillion | 22.35% | 1.25x | $589.46 Million |
| Dongwha Pharm.Co.Ltd (000020) | $300.87 Billion | 3.12% | 0.25x | $76.07 Million |
| Yuhan Corp Preferred (000105) | $2.15 Trillion | 3.29% | 0.37x | $3.71 Billion |
| Yuyu Pharma (000220) | $120.36 Billion | -5.97% | 0.65x | $29.69 Million |
| Ildong Holdings Co Ltd (000230) | $310.17 Billion | 8.80% | 0.65x | $48.77 Million |
| Samil Pharm (000520) | $66.60 Billion | 0.00% | 0.82x | $103.58 Million |
| Donga Socio Holdings (000640) | $1.03 Trillion | 5.64% | 0.91x | $204.37 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $278.79 Million |
| JW Pharmaceutical Corp (001065) | $276.31 Billion | -3.96% | 1.36x | $246.19 Million |
| Samsung Pharm (001360) | $46.24 Billion | -2.15% | 1.82x | $64.85 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $165.68 Billion | 10.17% | 0.83x | $27.46 Million |